Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts.


Journal

Cancer research
ISSN: 1538-7445
Titre abrégé: Cancer Res
Pays: United States
ID NLM: 2984705R

Informations de publication

Date de publication:
01 Sep 2019
Historique:
received: 31 01 2019
revised: 16 04 2019
accepted: 23 05 2019
pubmed: 31 5 2019
medline: 26 9 2019
entrez: 31 5 2019
Statut: ppublish

Résumé

Identifying robust biomarkers of drug response constitutes a key challenge in precision medicine. Patient-derived tumor xenografts (PDX) have emerged as reliable preclinical models that more accurately recapitulate tumor response to chemo- and targeted therapies. However, the lack of computational tools makes it difficult to analyze high-throughput molecular and pharmacologic profiles of PDX. We have developed Xenograft Visualization & Analysis (Xeva), an open-source software package for

Identifiants

pubmed: 31142512
pii: 0008-5472.CAN-19-0349
doi: 10.1158/0008-5472.CAN-19-0349
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

4539-4550

Commentaires et corrections

Type : CommentIn

Informations de copyright

©2019 American Association for Cancer Research.

Auteurs

Arvind S Mer (AS)

Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.

Wail Ba-Alawi (W)

Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.

Petr Smirnov (P)

Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.

Yi X Wang (YX)

Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.

Ben Brew (B)

Hospital for Sick Children, Toronto, Ontario, Canada.

Janosch Ortmann (J)

Département de Management et Technologie, Université du Québec à Montréal, Montreal, Quebec, Canada.

Ming-Sound Tsao (MS)

Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.

David W Cescon (DW)

Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.

Anna Goldenberg (A)

Hospital for Sick Children, Toronto, Ontario, Canada.
Department of Computer Science, University of Toronto, Toronto, Ontario, Canada.
Vector Institute, Toronto, Ontario, Canada.

Benjamin Haibe-Kains (B)

Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada. benjamin.haibe.kains@utoronto.ca.
Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.
Department of Computer Science, University of Toronto, Toronto, Ontario, Canada.
Vector Institute, Toronto, Ontario, Canada.
Ontario Institute for Cancer Research, Toronto, Ontario, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH